GSK rubbishes media review claims

LONDON – GlaxoSmithKline’s European media director Andy Bolden has flatly denied that the pharmaceutical and consumer healthcare giant is reviewing its £300m global media account.

No Responses to “GSK rubbishes media review claims”

Post a Comment